Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally - and taking the headline - the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases and conditions that have not been previously discussed by the company.

The complete PR:

Cellceutix Identifies Drug Candidates for Gram-Negative and Candida Fungal Infections
Company Completing IND Application to Commence Clinical Trial of New Psoriasis Drug Prurisol

Company Completing IND Application to Commence Clinical Trial of New Psoriasis Drug Prurisol

Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that it has made significant breakthroughs with its portfolio of novel drug candidates for infectious disease, including fungal infections and Gram-negative bacterium. Extensive screening has identified five promising drug candidates for fungal infections, including PMX1502 and PMX1408 as stand-outs for anti-Candida fungal activity to be used for both oral and disseminated candidiasis. Current therapies today are not only relatively ineffective, but are seriously limited by recurrence, resistance and systemic toxicity.

In particular, PMX1502 shows robust efficacy, systemic use and selectivity in a disseminated candidiasis animal model. The compound showed cidal activity rather than static effect and significant reduction in fungal tissue burden. The activity of PMX1408 against Candida and Aspergillus warrants further development of the compound as a topical treatment for hard-to-treat infections. Given the limitations of current standards of care, the Company believes that new drugs for treatment of these indications are highly desirable.

Drug-resistant bacteria are quickly becoming a source of global concern and were recently the subject of a World Health Organization warning in listing antibiotic resistance as one of the top three public health threats of this century. According to a special editorial in the Lancet this month, “superbugs,” or drug-resistant bacteria, threaten to erase a century of medical advances. This has created an urgent need for development of new drugs, especially for drugs focused on Gram-negative infections, which are typically far more difficult to treat than Gram-positive infections.

“The alarms have sounded globally, signaling the dire need for new antibiotics and the premium prices that promising compounds can command. Roche recently jumped back into the antibiotic markets by agreeing to pay up to $548 million for a Phase II antibiotic targeting Gram-negative pathogens,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “We believe there is a great interest in the pharmaceutical industry for clinical-stage gram-negative compounds. We are extremely motivated to move the drugs forward as quickly as possible to satisfy this interest. The latest research with PMX1502 and PMX1408 well positions us to move into the multi-billion-dollar anti-fungal and Gram-negative bacterium markets. We knew we were gaining substantial assets with the PolyMedix acquisition, but this is evolving into more than even I expected at this point.”

Regarding bacterial infections, Cellceutix researchers have identified a series of host defense protein (HDP)-mimetic compounds that rapidly kill a variety of clinically-important Gram-negative pathogens. Infections caused by these pathogens are very difficult to treat because the bacteria are typically multi-drug resistant, which can lead to life-threatening conditions. The Company’s compounds are active against some of the most problematic pathogens, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli and Acinetobacter baumannii as well as highly multi-drug resistant ndm-1-producing K. pneumoniae. The Company’s compounds exhibit low toxicity against mammalian cell types, with in vivo studies showing several of the compounds to be active in animal infection models.

Separately, Cellceutix today announced that it has received the Chemistry, Manufacturing and Controls (“CMC”) section from NYSE-listed Dr. Reddy’s Laboratories Ltd. required for its Investigational New Drug (“IND”) application for Prurisol, the Company’s lead anti-psoriasis compound.

Cellceutix’s dermatology team is currently incorporating the CMC section into the IND for submission to the U.S. Food and Drug Administration (“FDA”). The Company is developing Prurisol under FDA guidance that a 505(b)(2) designation is an appropriate developmental pathway.

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is being readied for a Phase 2/3 clinical trial at sites in the U.S. and Europe. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is set to begin a Phase 2b trial in the first half of 2014 for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy for multi-drug resistant bacteria or a dosing regimen that is shorter than currently marketed antibiotics. Cellceutix has formed research collaborations with world renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact:
INVESTOR AND MEDIA CONTACT:
Cellceutix Corp.
Leo Ehrlich
(978) 236-8717

Cellceutix Corp. (CTIX) Stock Quote and News:

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and identity product that is being developed by Shelton, Connecticutt-based NXT-ID, Inc. (OTCQB:NXTD).

NXT-ID was founded by former senior management at Technest Holidings and its subsidiary, Genex Technologies, industry-leading companies in the field of advanced imaging, including 3D and 360-degree technologies. NXT-ID has licensed these companies’ technologies, as well as technologies from 3D-imaging expert Geometrix. Utilizing these technologies with their own intellectual property, NXT-ID is launching MobileBio, a technology that secures consumers’ mobile platforms through authentication and encryption. As the trend continues to move towards mobile transactions, there is a great need for advanced solutions to protect users’ and institutions’ information more effectively than the inherently insecure standards of payment today. MobileBio is the cornerstone of NXT-ID’s end-to-end solutions to bridge the gap.

The company has developed Biocloud, a cloud-based biometric identify authentication solution for consumer applications and corporate security. The company’s MobileBio Voicematch platform can be bootstrapped to several platforms, such as smartphones, tablets and computers, to embed additional security via voice recognition biometrics to ensure the identity of a user before allowing access to countless applications. Voicematch is forecast to be available in the first quarter of 2014. Along the same lines, MobileBio Facematch employs modular facial recognition to devices for superior authentication and encryption. Several configurations are possible, including hosting the technology on a device or remotely in the cloud by marrying Facematch with Biocloud. According to NXT-ID, Facematch will soon be available in an app for iPhone and Android systems.

“We are pleased with the continued development of the Wocket™,” says David Tunnell, CTO of NXT-ID. “Our approach eliminates the need for passwords by authenticating identity in a natural way for users. With Voicematch™, users can simply ask for a user-defined name of a card and the Wocket™ then automatically programs the NXTCard with the card of their choice.”

A lot of noise has been made recently about improving security on devices of all types. Apple (Nasdaq:AAPL) was even criticized for not including their thumbprint technology on the latest generation of iPhones 5C’s to prevent unauthorized use. While thumbprint technology is certainly a more advanced security feature and will be welcomed by the masses, what NXT-ID is taking things to the next level with voice and facial recognition. In short (and layman’s terms), this is some pretty cool stuff.

NXT-ID is an early-stage company that just went public in August via an S-1 registration, but interest seems to remain strong with shares climbing from initially around $1.50 to as high as $6.00 before pulling back to current levels around $3.50. As the products start rolling-out to the public, even more investors (and other companies) may start taking note of this upstart and the cutting-edge technology it possesses. Proper due diligence is, as always, encouraged.

NXT-ID, Inc. (NXTD) Stock Quote and News:

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome.

With the success seen by companies like Vringo Inc. (AMEX: VRNG) in their lawsuit against AOL Inc. (NYSE: AOL) and VirnetX (ASE: VHC) in their case against Apple Inc. (NASDAQ: AAPL), Blue Calypso is a stock worth watching closely as this date approaches. Successful litigation could set the stage for similar outcomes against many other companies in the space.

“We believe that there may be a significant and growing number of companies infringing our patents. We intend to pursue every legal remedy at our disposal to protect our core intellectual property and have initially targeted companies that are leaders in various business segments where we compete. A successful outcome would prove out the value of our intellectual property portfolio and validate the market potential of Blue Calypso’s technologies,” said Bill Ogle, Chairman and Chief Executive Officer of Blue Calypso in the recent press release.

“We are confident that Claim Construction Hearings will be scheduled for each of these cases toward the end of 2013, with full jury trials expected in mid-2014, if licensing agreements or other remediation is not achieved prior to litigation,” added Mr. Ogle in the press release, when discussing the actions against other companies in the space.

These cases are being represented by recognized leaders in patent protection and litigation, including Farney Daniels P.C. in its claim against LivingSocial, and Fish & Richardson P.C. in its claims against Groupon, Foursquare, Yelp, IZEA and MyLikes.

Blue Calypso (BCYP) Stock Quote and News:

One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact. Even sports legends Shaquille O’Neal and Reggie Jackson being onboard as both investors and brand ambassadors to Soupman, inc. (OTCQB: SOUP) haven’t lifted shares. In fact, shares actually slipped lower after announcing Shaq, one of the biggest names in basketball history and a promotional wizard, in late 2011.

Surely hoping that the announcement of a new star partner will have a more beneficial impact on market valuation is Digital Development Group Corp. (OTCBB: DIDG) with Wednesday evening’s report that actor Charlie Sheen has joined the team. The Hollywood-based company is involved in acquisition and distribution of Over the Top, or “OTT,” television content.

Obviously, big-budget companies like Netflix and Hulu tailor their business towards distribution of mainstream programs and movies, but smaller companies like DigiDev, as it is often called, are initially focused on creating original content for its growing library of material. For a small fee, the company currently offers access to collections through channels such as its “Sci-Fi Station” with cult classics in horror, science fiction, etc. and “Synapse Films,” which contains a wide array of “features, documentaries and clips…be it weird, offbeat, cult, sexy, exploitation, B movies, or other strange and unusual titles,” to name a few.

Future offerings include channels featuring people like Kato Kaelin, made famous as a witness in the O.J. Simpson murder trial, former porn star (and vice presidential candidate) Marilyn Chambers, and now Charlie Sheen.

Sheen, the son of Hollywood icon Martin Sheen and brother of actor Emilio Estevez, has made a positive name for himself as a star in blockbuster movies such as Platoon and Wall Street and TV show Two and a Half Men, but also has had his personal life criticized with reports of alcohol and drug abuse as well as alleged domestic violence.

Describing his company as “misfits of TV,” DigiDev president Joe Q. Bretz, says that he has been working with Sheen for “quite some time” to ink the new partnership. Bretz explained that “misfits change the world, and we intend on creating something alongside Charlie that will be historical.”

“A long time ago on a movie set far, far away, a character I once played said, ‘life all comes down to a few moments, and this is one of them,’” commented Sheen in the corporate statement. “DigiDev is one of these moments. For years I have longed for a home and an outlet for the tsunami that is my brain. Batten down the Forbes hatches; I hope DigiDev can hold its breath for a long time.”

Sheen will serve as curator of DigiDev’s channels and as an advisor for special content acquisitions, according to the company. No filings with the SEC have been made as of the time of this writing to sift through for more details of the contract.

From the investor side, traders will be watching on Thursday to see if the news can make a splash. Shares of DIDG have been on the slide since it began trading in April 2012 around $1.30 per share, closing Wednesday at 8.5 cents, for gains of 10.4 percent on the day.

Shares had sunk as low as 5 cents in January, before spiking to 20.5 cents about two weeks later. Will this be the kick it needs for the stock to identify the nickel mark as a true bottom and start a new uptrend? Well, only time will deliver that answer, but this is an interesting development for fans of DigiDev and Hollywood’s bad boy. Proper due diligence is, as always, encouraged.

Article submitted by AllPennyStocks.com

Digital Development Group (DIDG) Stock Quote and News:

Shares of Sunvalley Solar, Inc. (OTCBB: SSOL) are rising in trading Monday morning after the solar power technology company disclosed a new contract to 87.5-kilowatt solar system installation contract from Corporate Logistics in City of Industry, California.

The contract is for a system capable of generating 131,146 kilowatt hours of electrical power each year, utilizing 350 pieces of high efficiency 250-watt polycrystalline solar panels, according to Walnut, California-based Sunvalley. The installation is slated to begin mid-2013.

“Corporate Logistics’, an existing customer since 2008, selection of Sunvalley for this contract shows their trust and confidence in our quality and our expertise. Sunvalley continually strives to be a leading supplier of high quality solar systems,” said James Zhang, chief executive of Sunvalley Solar.

No values of the contracts were disclosed.

Shares of SSOL have held a base in the area of $0.003 in 2013 and have spiked as high as $0.0202 in mid-February (nearly a 600 percent move). The gains were sustained, though, with prices dropping back down near the bottom support level.

With the news today, shares have perked back up by about 60 percent midway through Monday’s trading, printing $0.0069 with more than 3.5 million shares changing hands. In the past 52 weeks, shares are down about 50 percent.

Sunvalley Solar (SSOL) Stock Quote and News:

The online gambling business is a hotbed of activity lately with Nevada, Delaware and New Jersey passing legislation permitting Internet betting with real money.  Bills have already been introduced in several other states as well, including California, Iowa and Mississippi, to legalize online wagering.

There’s good reason for the markets buzzing about the potential revenues from online betting.  The global online Read More

ALR Technologies Inc. (OTCBB: ALRT) took a big step in the direction of commercializing their Health-e-Connect Diabetes Management Program with news this week that the company has partnered with the Mid-America Coalition on Health Care, or MACHC.  The new pact means that MACHC will be introducing the ALRT program for pilot participation by its membership, which consists of 67 organizations representing more than 500,000 employees in the greater Kansas City area. Read More

Reality gaming social network company Face Up Entertainment Group, Inc. (OTCBB: FUEG) said late Wednesday that it has partnered with Bad Beat on Hunger, Inc. in the battle against childhood hunger in the U.S.  Bad Beat on Hunger is a venture between ForeverGreen International (OTCBB: FVRG) and the Happy Children Foundation helping to put Read More

Shares of Electronic Control Security, Inc. (OTCBB: EKCS) have soared ahead in Friday morning trading after the company said that it has received a prime contract award from the Department of the Navy, Space and Naval Warfare Systems Center Atlantic (SPAWAR). Read More

Investors are used to hearing about lithium battery technologies for use in automobiles, but Balqon Corporation (OTCBB: BLQN) is taking them from the street to the water. On Friday, the Harbor City, California-based developer of electric vehicles, drive systems and lithium battery storage systems said that it has delivered and installed its HIQAP high energy Read More